Cholesterol and its transport

PROF. DR. SHAKIR F. T. ALAARAJI

PH. D. BIOCHEMISTRY


UNIVERSITY OF ANBAR

COLLEGE OF EDUCATION FOR PURE


SCIENCES

CHEMISTRY DEPARTMENT

Cholesterol - structure



27 carbons



Cholesterol importance

- A stabilizing component of cell membranes
- A precursor of bile salts
- A precursor of steroid hormones
- A cholesterol precursor is converted to cholecalciferol (vit. D)

Cholesterol sources


- 1) Endogenous biosynthesis (liver 50%, skin, intestine)
- 2) Exogenous intake (from the diet)

Cholesterol in the blood:

- 1) The free form (1/3)
- 2) Cholesterol esters (2/3)

Cholesterol metabolism


- Sources of cholesterol: 1. the diet, 2. de novo synthesis from acetyl-CoA (liver)
- Utilization of cholesterol: 1. the synthesis of bile acids, 2. building block for cell membranes, 3. stored in the form of lipid droplets, following esterification with fatty acids, 4. formation of VLDL (supply other tissues)
- The liver takes up from the blood and degrades lipoprotein complexes containing cholesterol (HDL)



Cholesterol balance:

The body contains: 150 g of cholesterolu

3-5 g of bile acids



Biosynthesis of cholesterol

In the cytosol + ER

Precursor - acetyl CoA from:


- 1. The β -oxidation of fatty acids
- 2. The oxidation of ketogenic amino acids
- 3. The pyruvate dehydrogenase reaction

The reducing agent - NADPH

- from PPP

Energy for synthesis

- hydrolysis of CoA and ATP



1) Formation of 3-HMG CoA:


- In the biosynthesis of ketone bodies (in the mitochondria)
- ➢ In the cytosol!

2) Reduction to mevalonate:

- NADPH
- HMG CoA reductase (in the ER)


Regulation of HMG CoA reductase:

- A. Control of transcription (cholesterol)
- B. Proteolysis (cholesterol)
- C. Phosphorylation (hormones)



Regulation of HMG CoA reductase


1. Transcriptional control:



Transcription factor - SREBP (sterol-regulatory element-binding proteins)

- transcription of the HMG CoA reductase gene (binds to SRE sterol-regulatory element)
- a) High cholesterol level SREBP is bound in ER to SCAP (SREBP cleavage-activation enzyme)
- b) Low cholesterol level transfer to GA cleavage binding to DNA


2. Proteolytic degradation of HMG CoA reductase:



High levels of cholesterol and bile acids

binding to HMG CoA reductase - structural changes - more susceptible to proteolysis

3. Regulation by phosphorylation:



Glucagon

- increase dephosphorylation activation \geq
- AMP-activated proteinkinase
- the need of ATP

 \geq

Insulin


3) Phosphorylation

4) Decarboxylation to isopentenyl diphosphate ("activated isoprene")

> ATP

intermediate for the formation of other isoprenoids

(tocopherol, ubiquinone, carotenoids)



Isopentenyl diphosphate


5) Isomerization

6) Condensation to geranyl diphosphate

7) Formation of farnesyl diphosphate

- the addition of another isopentenyl diphosphate
- intermediate of other polyisoprenoids (dolichol, ubiquinone)

8) Dimerization to squalene




9) Cyclization of squalene

- > oxygen
- monooxygenase (cytochrome P450 system)

10) Formation of cholesterol

- cleavage of 3 methyl groups
- double bond changes



Bile acid metabolism

Bile acids:

-synthesized in the liver from cholesterol


-amphipathic, act as detergents

-linked with an amino acid (glycine or taurine) - bile salts


-primary bile acids are formed in the liver, secondary bile acids in the intestine (by dehydroxylation of the primary bile acids)

Lipid digestion:

-facilitate the solubilization of dietary lipids during the process of digestion by promoting micelle formation



Bile acids - the structure




Synthesis of bile acids


Hydroxylation

(rate-limiting reaction)

- Reduction of the double bond
- Further oxidation
- Cleavage of 3 C
- A carboxyl group



Metabolism of bile salts (exlusively in the liver)




- 1. The biosynthesis of bile acids from cholesterol
- 2. The conjugation with the amino acids
- **3.** The concentration in the gallbladder by removal of water

4. a 5. Intestinal bacteria in the colon produce enzymes that can attack and alter the bile salts

6. Most of the bile acids are reabsorbed from the intestine and, following transport to the liver, returned once again into the bile (enterohepatic circulation)


Conjugation of bile salts



Lipoproteins

Function:

Lipid transport (cholesterol, cholesterol esters, triacylglycerols, phospholipids)




A nucleus: triacylglycerols, cholesterol esters


A shell: phospholipids, apoproteins, cholesterol

Separation of lipoproteins

a) Ultracentrifugation (density)

b) elecroforesis (size)






Characteristics of the major lipoproteins

Lipoprotein	Origin	Halftime in blood	Major apoproteins	Major lipids	Function
Chylomicrons	intestine	5-15 min	B-48, C-II, E	TG	Deliver dietary lipids
VLDL	liver	2h	B-100, E, C-II	TG	Deliver endogenous lipids
IDL	plasm	2h	B-100, E, C-II	TG/CHE	Precursor of LDL
LDL	plasm	2-4 dny	B-100	CHE	Deliver cholesterol to cells
HDL (nascent)	liver, intestine, plasm	10h ?	A-I, C-II, E	PL/CHE	Reverse cholesterol transport

Composition of lipoproteins




Apoproteins

Major function:


structure, solubility, activation of enzyme, ligands for receptors

Apoprotein	Function
Аро А-І	activates LCAT, structural component of HDL
Аро В-48	Assembly and secretion of chylomicrons
Аро В-100	VLDL assembly and secretion; structural protein of VLDL, IDL and LDL; ligand for LDL receptor
Apo C-II	Activator of lipoprotein lipase (LPL)
Аро Е	ligand to LDL receptor; ligand to Apo E receptor

Lipoproteins - metabolism



Metabolism of chylomicrons



Lipoprotein lipase (LPL)

- On capillary walls in adipose tissue and muscle
- Cleaves TG

Chylomicrons remnants

- receptors in the liver, lysosoms

Chylomicrons

Formation:

- intestinal epithelial cells
- secretion into the lymph


Major apoproteins:

Apo B-48 (nascent)


Apo C-II, Apo E (from HDL)

Function:

Deliver dietary lipids



Metabolism of VLDL, IDL and LDL



VLDL

Formation:

- > liver
- secretion into the blood
- lipoprotein lipase

Major apoproteins:

Apo B-100 (nascet)

Apo C-II, Apo E (from HDL)

Function:

- Deliver endogenous lipids


IDL

hepatic triacylglycerol lipase (HTGL)

LDL

- a) 60% back to the liver (apo B-100 receptor)
- b) 40% to extrahepatic tissues (adrenocortical and gonadal cells)
- c) The excess nonspecific uptake by macrophages (scavenger cells) in the cell wall (atherosclerosis)

Metabolism of HDL



HDL

Formation:

- 1. Liver, intestine (nascent HDL)
- 2. Plasm (binding of cholesterol and phospholipids from other lipoproteins to Apo A-I)

Mature HDL

Accumulation of cholesterol esters in the core

Apoproteins: Apo A-I, Apo C-II, Apo E


Function:

- 1. <u>Reverse cholesterol transport = return the cholesterol to the liver</u>
- Vascular tissue (protection agains atherosclerosis)
- LCAT (lecitin cholesterol acyltransferase) formation of cholesterol esters!
- 2. Interaction with other lipoproteins
- Transfer of apoproteins (Apo C-II, Apo E) and lipids (CETP cholesterol ester transfer protein)

Fate of HDL cholesterol:

receptors in the liver, scavenger receptors, transfer to VLDL (to the liver)

Cholesterol uptake by receptor-mediated endocytosis:



Lipoprotein receptors

LDL receptor

Ligands - Apo B-100, Apo E (VLDL, IDL, LDL, chylomicron remnants) Familial hypercholesterolemia

Changes in the number of LDL receptors, in binding of LDL and in the postreceptor binding process - accumulation of LDL in the blood atherosclerosis

Macrophage scavenger receptor

- nonspecific (oxidatively modified LDL)
- not down-regulated!

Foam cells - macrophages engorged with lipid

accumulation - atherosclerosis

Pictures used in the presentation:

Marks' Basic Medical Biochemistry, A Clinical Approach, third edition, 2009 (M. Lieberman, A.D. Marks)

Textbook of Biochemistry with Clinical Correlations, sixth edition, 2006 (T.M. Devlin)